Our NGS Panel Details

Please note: For all of the assays detailed below, sequence data (from the specified regions) will only be assessed for the presence of unique coding variants contained within version 79 of the COSMIC database. Any variants outside of this designation are not routinely assessed or reported.

For details of our legacy NGS panels, including previous revisions of MGP-4, click here

MGP-4 version 5

Our ‘Flexible’ Targeted Therapies Panel – assessing Hotspots, Copy Number Gains and Gene Fusions

This is our  entirely bespoke Multi-Gene Panel (MGP), intended to help guide the use of targeted anti-cancer therapies in common solid tumours. Launched in mid-2020, following extensive validation and ISO15189 accreditation, we were able to replace all of our preceding panels (MGP-1,2 & 3) with this very robust, sensitive and highly informative solution. MGP-4 is also very cost effective, providing as much clinically actionable information as many larger and considerably more expensive panels.

It is available in a fully flexible format, with service users able to choose only the DNA component (for hot-spot variants & copy number gains- CNGs), only the RNA component (for gene fusions), or both DNA/RNA combined. With combined testing, both components can be requested ‘upfront’ to save time, or alternatively with an option to reflex to RNA analysis only if the DNA based analysis proves uninformative, thus saving money and potentially precious tissue.

MGP-4 combines the highest utility targets from our previous three panels and also allows formal* reporting of copy number gains (CNGs) in relevant genes and suitable samples. However, please note that relative tumour content requirements are higher for CNG reporting (>20%) than for hotpots (>5%).

*CNGs have previously been reported, but only as incidental findings, requiring appropriate confirmation before being used for clinical decision making.

The following genes are included for potential ‘future proofing’. These will NOT be analysed or reported routinely until further notice.

MGP-5

Our Homologous Recombination Deficiency Panel

This is our latest Multi-Gene Panel (MGP), offering comprehensive sequencing of the full coding region of 15 key genes (see below) involved in the homologous recombination repair pathway. This is intended to help guide the use of therapies such as PARPi inhibitors in certain tumour types (e.g. Breast, Prostate, Ovarian, Pancreatic)  which may exhibit homologous recombination deficiencies. Please note: 1) This test does not provide a measure of genomic instability.

SNVs & Small Indels